Published in J Clin Invest on July 01, 1966
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36
The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. Proc Natl Acad Sci U S A (2006) 1.96
CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc Natl Acad Sci U S A (2011) 1.90
Leukocyte beta-glucosidase in homozygotes and heterozygotes for Gaucher disease. Am J Hum Genet (1980) 1.56
Expression of human Gaucher disease gene GBA generates neurodevelopmental defects and ER stress in Drosophila eye. PLoS One (2013) 1.45
The metabolism of amino acids, peptides, and disulfides in lysosomes of fibroblasts cultured from normal individuals and those with cystinosis. J Exp Med (1970) 1.43
The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase. FEBS J (2010) 1.42
A glucocerebrosidase fusion gene in Gaucher disease. Implications for the molecular anatomy, pathogenesis, and diagnosis of this disorder. J Clin Invest (1990) 1.41
Gaucher disease: isolation and comparison of normal and mutant glucocerebrosidase from human spleen tissue. Proc Natl Acad Sci U S A (1978) 1.26
Ultrasensitive in situ visualization of active glucocerebrosidase molecules. Nat Chem Biol (2010) 1.26
Effective cell and gene therapy in a murine model of Gaucher disease. Proc Natl Acad Sci U S A (2006) 1.25
Murine models of acute neuronopathic Gaucher disease. Proc Natl Acad Sci U S A (2007) 1.23
Substrate reduction therapy of glycosphingolipid storage disorders. J Inherit Metab Dis (2006) 1.16
Ceramide function in the brain: when a slight tilt is enough. Cell Mol Life Sci (2012) 1.12
Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy. J Inherit Metab Dis (2010) 1.10
Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Des Devel Ther (2012) 1.10
Enzyme replacement therapy: conception, chaos and culmination. Philos Trans R Soc Lond B Biol Sci (2003) 1.10
Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl. Proc Natl Acad Sci U S A (2010) 1.09
Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. J Inherit Metab Dis (2011) 1.07
Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proc Natl Acad Sci U S A (2011) 1.06
X-ray and biochemical analysis of N370S mutant human acid β-glucosidase. J Biol Chem (2010) 1.04
Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention. Philos Trans R Soc Lond B Biol Sci (2003) 0.98
The saccadic and neurological deficits in type 3 Gaucher disease. PLoS One (2011) 0.93
Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones. Proc Natl Acad Sci U S A (2013) 0.88
Upregulation of proinflammatory cytokines in the fetal brain of the Gaucher mouse. J Korean Med Sci (2006) 0.87
Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase. Biochem Pharmacol (2006) 0.87
Sphingolipidoses. J Clin Pathol Suppl (R Coll Pathol) (1974) 0.81
Benefits from unearthing "a biochemical Rosetta Stone". J Biol Chem (2010) 0.80
Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice. Mol Ther (2015) 0.80
Identification of potent and selective glucosylceramide synthase inhibitors from a library of N-alkylated iminosugars. ACS Med Chem Lett (2010) 0.80
A sensitive gel-based method combining distinct cyclophellitol-based probes for the identification of acid/base residues in human retaining β-glucosidases. J Biol Chem (2014) 0.78
The LIMP-2/SCARB2 binding motif on acid β-glucosidase: basic and applied implications for Gaucher disease and associated neurodegenerative diseases. J Biol Chem (2014) 0.77
Defective Self-Renewal and Differentiation of GBA-Deficient Neural Stem Cells Can Be Restored By Macrophage Colony-Stimulating Factor. Mol Cells (2015) 0.76
Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy. Core Evid (2016) 0.75
Clinical manifestations and management of Gaucher disease. Clin Cases Miner Bone Metab (2015) 0.75
Bone marrow involvement in Gaucher disease at MRI : what long-term evolution can we expect under enzyme replacement therapy? Eur Radiol (2015) 0.75
Investigations on therapeutic glucocerebrosidases through paired detection with fluorescent activity-based probes. PLoS One (2017) 0.75
Successful screening for Gaucher disease in a high-prevalence population in tabuleiro do Norte (northeastern Brazil): a cross-sectional study. JIMD Rep (2011) 0.75
[Angiokeratoma corporis diffusum (Fabry)--Lipoid thesaurismosis]. Arch Dermatol Forsch (1971) 0.75
The genetic mismanagement of complex lipid metabolism. Bull N Y Acad Med (1971) 0.75
Long-term response in biochemical markers of bone turnover during enzyme replacement therapy in a case-series of patients with Gaucher disease type I from Northern Greece. Hippokratia (2017) 0.75
Enzymic defects in lipid-storage diseases. Biochem J (1970) 0.75
Treatment of profound thrombocytopenia in a patient with Gaucher disease type 1: Is there a role for substrate reduction therapy. Mol Genet Metab Rep (2017) 0.75
Stabilization of glucocerebrosidase by active-site occupancy. ACS Chem Biol (2017) 0.75
A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem (1957) 173.99
METABOLISM OF GLUCOCEREBROSIDES. II. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHER'S DISEASE. Biochem Biophys Res Commun (1965) 5.63
THE METABOLISM OF GLUCOCEREBROSIDES. I. PURIFICATION AND PROPERTIES OF A GLUCOCEREBROSIDE-CLEAVING ENZYME FROM SPLEEN TISSUE. J Biol Chem (1965) 2.25
A reinvestigation of the cerebroside deposited in Gaucher's disease. J Biol Chem (1958) 1.42
Turnover of the fatty acids of rat brain gangliosides, glycerophosphatides, cerebrosides, and sulfatides as a function of age. J Lipid Res (1965) 1.15
Neurological signs in a juvenile form of Gaucher's disease. Acta Paediatr (1962) 1.14
Cerebroside synthesis in Gaucher's disease. J Clin Invest (1960) 1.08
Enzymic oxidation of cerebrosides: studies on Gaucher's disease. Biochim Biophys Acta (1962) 1.01
Concern Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med (2000) 29.03
Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med (1993) 7.29
Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science (1997) 6.66
Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med (1991) 6.09
Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med (1967) 5.63
Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA (2001) 5.54
Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science (1994) 4.50
Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci U S A (1996) 4.16
D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A (2000) 3.71
Prenatal genetic diagnosis. I. N Engl J Med (1970) 3.67
Mice that lack the interferon-gamma receptor have profoundly altered responses to infection with Bacillus Calmette-Guérin and subsequent challenge with lipopolysaccharide. J Exp Med (1993) 3.48
Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc Natl Acad Sci U S A (1996) 3.07
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation (2001) 2.55
Biosynthesis and function of gangliosides. Science (1976) 2.51
Niemann-Pick disease group C: clinical variability and diagnosis based on defective cholesterol esterification. A collaborative study on 70 patients. Clin Genet (1988) 2.50
High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. J Virol (1998) 2.47
The Niemann-Pick C1 protein resides in a vesicular compartment linked to retrograde transport of multiple lysosomal cargo. J Biol Chem (1999) 2.45
alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci U S A (1997) 2.43
Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med (1995) 2.39
Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther (2004) 2.38
A defect in cholesterol esterification in Niemann-Pick disease (type C) patients. Proc Natl Acad Sci U S A (1985) 2.38
The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick diseae. Proc Natl Acad Sci U S A (1966) 2.32
Prenatal genetic diagnosis (second of three parts). N Engl J Med (1970) 2.29
Purification of serine racemase: biosynthesis of the neuromodulator D-serine. Proc Natl Acad Sci U S A (1999) 2.27
Functional incorporation of ganglioside into intact cells: induction of choleragen responsiveness. Proc Natl Acad Sci U S A (1976) 2.14
The sphingolipidoses. N Engl J Med (1966) 2.13
Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A (2000) 2.00
Type C Niemann-Pick disease. Lysosomal accumulation and defective intracellular mobilization of low density lipoprotein cholesterol. J Biol Chem (1988) 1.98
Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry's disease. N Engl J Med (1973) 1.94
D-serine as a neuromodulator: regional and developmental localizations in rat brain glia resemble NMDA receptors. J Neurosci (1997) 1.93
Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci U S A (1990) 1.88
Low-back pain in pregnancy. Spine (Phila Pa 1976) (1987) 1.84
Diagnosis of gaucher's disease and niemann-pick disease with small samples of venous blood. Science (1967) 1.78
Phosphatidylethanol formation via transphosphatidylation by rat brain synaptosomal phospholipase D. J Neurochem (1987) 1.77
Gangliosides in DNA virus-transformed and spontaneously transformed tumorigenic mouse cell lines. Proc Natl Acad Sci U S A (1969) 1.76
Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2007) 1.75
Adult Gaucher's disease: kindred studies and demonstration of a deficiency of acid beta-glucosidase in cultured fibroblasts. Am J Hum Genet (1972) 1.74
Molecular biology mechanisms in the radiation induction of pulmonary injury syndromes: interrelationship between the alveolar macrophage and the septal fibroblast. Int J Radiat Oncol Biol Phys (1992) 1.73
Regulation of NMDA receptors by cyclin-dependent kinase-5. Proc Natl Acad Sci U S A (2001) 1.73
Lactosylceramide galactosidase: comparison with other sphingolipid hydrolases in developing rat brain. Brain Res (1969) 1.72
Change involving a viral membrane glycoprotein during morphogenesis of group B arboviruses. Virology (1972) 1.69
Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease. N Engl J Med (1974) 1.67
Metachromatic leukodystrophy: diagnosis with samples of venous blood. Science (1968) 1.67
Immunological and biophysical separation of dengue-2 antigens. J Virol (1971) 1.66
Mutations of glucocerebrosidase: discrimination of neurologic and non-neurologic phenotypes of Gaucher disease. Proc Natl Acad Sci U S A (1982) 1.64
The proteins of Japanese encephalitis virus. Virology (1971) 1.63
A lysosomal storage disorder in mice characterized by a dual deficiency of sphingomyelinase and glucocerebrosidase. Biochim Biophys Acta (1980) 1.63
Isolation and characterization of glucocerebrosidase from human placental tissue. J Biol Chem (1973) 1.62
Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease. Blood Cells Mol Dis (2000) 1.61
Isolation and relationship of human hexosaminidases. J Biol Chem (1974) 1.61
Effects of alterations in cellular iron on biosynthesis of the transferrin receptor in K562 cells. Mol Cell Biol (1985) 1.61
Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease. Neurology (2006) 1.57
Enzyme replacement therapy in Gaucher's disease: large-scale purification of glucocerebrosidase suitable for human administration. Proc Natl Acad Sci U S A (1977) 1.56
Type-C Niemann-Pick disease: low density lipoprotein uptake is associated with premature cholesterol accumulation in the Golgi complex and excessive cholesterol storage in lysosomes. Proc Natl Acad Sci U S A (1988) 1.56
Decreased systolic blood pressure through operant conditioning techniques in patients with essential hypertension. Science (1971) 1.54
A genetic storage disorder in BALB/C mice with a metabolic block in esterification of exogenous cholesterol. J Biol Chem (1984) 1.54
Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. Br Heart J (1991) 1.50
IgM in a human neuropathy related to paraproteinemia binds to a carbohydrate determinant in the myelin-associated glycoprotein and to a ganglioside. Proc Natl Acad Sci U S A (1984) 1.49
Cocaine detoxification by human plasma butyrylcholinesterase. Toxicol Appl Pharmacol (1997) 1.49
Thyrotropin-ganglioside interactions and their relationship to the structure and function of thyrotropin receptors. Proc Natl Acad Sci U S A (1976) 1.48
Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation (2001) 1.46
Generation of nitric oxide and induction of major histocompatibility complex class II antigen in macrophages from mice lacking the interferon gamma receptor. Proc Natl Acad Sci U S A (1993) 1.45
Blood pressure morning surge and hostility. Am J Hypertens (1998) 1.45
Evidence for the close association of a glycoprotein with myelin in rat brain. J Neurochem (1973) 1.44
A clinical staging classification for type C Niemann-Pick disease. Neurology (1992) 1.40
Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc Natl Acad Sci U S A (2001) 1.40
Purification and properties of the two major isozymes of alpha-galactosidase from human placenta. J Biol Chem (1978) 1.39
Craniofacial injuries resulting from taxicab accidents in New York City. Ann Plast Surg (1996) 1.38
Clinical Trial of the Pan-Caspase Inhibitor, IDN-6556, in Human Liver Preservation Injury. Am J Transplant (2007) 1.36
Gaucher cells in chronic myelocytic leukemia: an acquired abnormality. Blood (1969) 1.36
Evidence that the major protein in rat sciatic nerve myelin is a glycoprotein. J Neurochem (1973) 1.34
Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. Proc Natl Acad Sci U S A (2000) 1.33
The base exchange enzymes and phospholipase D of mammalian tissue. Can J Biochem (1980) 1.33
Immunological and catalytic quantitation of splenic glucocerebrosidase from the three clinical forms of Gaucher disease. Am J Hum Genet (1983) 1.33
Negative dental experiences and their relationship to dental anxiety. Community Dent Health (1996) 1.32
Monoclonal IgM in a patient with paraproteinemic polyneuropathy binds to gangliosides containing disialosyl groups. Ann Neurol (1985) 1.32
Pain inhibition, nicotine, and gender. Exp Clin Psychopharmacol (1998) 1.31
Biosynthesis of glycolipids in virus-transformed cells. Biochim Biophys Acta (1974) 1.31
Niemann-Pick C1 protein: obligatory roles for N-terminal domains and lysosomal targeting in cholesterol mobilization. Proc Natl Acad Sci U S A (1999) 1.30
Development of multigene and regulated lentivirus vectors. J Virol (2000) 1.30
Absence of a specific ganglioside galactosyltransferase in mouse cells transformed by murine sarcoma virus. Proc Natl Acad Sci U S A (1974) 1.29
Demonstration of an alteration of ganglioside metabolism in Tay-Sachs disease. Biochem Biophys Res Commun (1969) 1.28
Neuronal cyclin-dependent kinase 5 activity is critical for survival. J Neurosci (2001) 1.28
A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Int J Obes (Lond) (2010) 1.28
Clinical spectrum of Niemann-Pick disease type C. Neurology (1989) 1.27
Constitutive achlorhydria in mucolipidosis type IV. Proc Natl Acad Sci U S A (1998) 1.26
Gaucher disease: isolation and comparison of normal and mutant glucocerebrosidase from human spleen tissue. Proc Natl Acad Sci U S A (1978) 1.26
Age of onset of dental anxiety. J Dent Res (1999) 1.26
Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease. J Inherit Metab Dis (2004) 1.26
The metabolism of sphingomyelin. I. Purification and properties of a sphingomyelin-cleaving enzyme from rat liver tissue. J Biol Chem (1966) 1.25